DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M.
Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Clin Neurol Neurosurg 2005;
107 (3) 187-190
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.